EMEA EXECUTIVE DIRECTOR INTERVIEW EU MEDICINES AGENCY
March 1st, 2006
BY ALAN OSBORN
THE EUROPEAN Medicines Agency (EMEA) stands ready to help pharmaceutical companies in the development and marketing of new drugs in an effort to halt and reverse the decline in the number of new medicines being brought to the world market. Similarly, the agency is preparing to undertake conditional approval of new drugs based on positive benefit/risk assessments even where the clinical data is incomplete. An interview with the EMEA executive director Thomas Lonngren left Manufacturing Chemist with the firm impression that EMEA is preparing to play ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.